Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Sponsor: Wuhan Createrna Science and Technology Co., Ltd
Summary
This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.
Official title: An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of MY008211A Tablets in Patients With PNH Paroxysmal Nocturnal Hemoglobinuria (PNH)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-11-30
Completion Date
2026-12-30
Last Updated
2025-04-18
Healthy Volunteers
No
Interventions
MY008211A tablets
Participants will receive MY008211A at a dose of 400 mg orally b.i.d
Locations (1)
Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences)
Tianjin, Tianjin Municipality, China